Paragonix Technologies Celebrates Clinical Milestone of over 2,000 Organs Preserved and Transported for Transplantation

Now over 1 in 5 Thoracic Organ Transplants are preserved using Paragonix Advanced Organ Preservation and Tracking Technology CAMBRIDGE, MASSACHUSETTS – August 17, 2022 - Paragonix Technologies, Inc. is announcing a…

Continue ReadingParagonix Technologies Celebrates Clinical Milestone of over 2,000 Organs Preserved and Transported for Transplantation

Paragonix Technologies Announces Expanded Adoption of their LIVERguard™ System at the 2022 American Transplant Congress

With clinical utilization at 8 U.S. Liver Transplant Centers since commercial introduction in January 2022, Paragonix recently showcased its donor liver technology at the 2022 American Transplant CongressCAMBRIDGE, MASSACHUSETTS – Paragonix…

Continue ReadingParagonix Technologies Announces Expanded Adoption of their LIVERguard™ System at the 2022 American Transplant Congress

Legacy of Hope Performs First Time Use and Clinical Support of Advanced Preservation Technology for Thoracic and Abdominal Organs

CAMBRIDGE, MASSACHUSETTS – January 11, 2022 – Paragonix Technologies, Inc., a leading provider of donor organ preservation and transport systems, announced the first time, combination use of LIVERguard™ and Paragonix SherpaPak® to…

Continue ReadingLegacy of Hope Performs First Time Use and Clinical Support of Advanced Preservation Technology for Thoracic and Abdominal Organs

Paragonix Technologies, Inc., Announces First Successful Use of Paragonix SherpaPak™ Cardiac Transport System in Pediatric Transplant Recipients

  • Post author:
  • Post category:News

Paragonix Technologies, Inc. today announced that the first series of pediatric donor hearts preserved and transported using Paragonix SherpaPak Cardiac Transport System occurred at University of Florida Health (UF Health) and Le Bonheur Children's Hospital (TN). Starting in Q1 2019, Paragonix SherpaPak™ CTS have been shipped with heart connectors covering most aortic diameters, permitting the anchoring of variously sized hearts, including small pediatric hearts, to its proprietary suspension system for improved donor heart transport.

Continue ReadingParagonix Technologies, Inc., Announces First Successful Use of Paragonix SherpaPak™ Cardiac Transport System in Pediatric Transplant Recipients

Paragonix Technologies, Inc. Announces FDA Clearance and U.S. Launch of the Paragonix SherpaPak™ Pancreas Transport System

  • Post author:
  • Post category:News

Paragonix Technologies, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Paragonix SherpaPak™ Pancreas Transport System (PTS). Starting immediately, the Paragonix SherpaPak™ PTS will be commercially available to pancreas transplant centers and Organ Procurement Organizations. The Paragonix SherpaPak PTS provides unprecedented thermal and physical protection to the donor pancreas during transport from donor to recipient patients.

Continue ReadingParagonix Technologies, Inc. Announces FDA Clearance and U.S. Launch of the Paragonix SherpaPak™ Pancreas Transport System

Surgeons at Duke University Hospital Use Advanced Preservation and Transportation System to Safeguard Donor Heart During Journey Between Donor and Recipient

  • Post author:
  • Post category:News

DURHAM, N.C.--(BUSINESS WIRE)-Duke University Hospital has transported its first donor heart using the only commercially available FDA cleared and CE marked system for cold donor heart storage and transport. The…

Continue ReadingSurgeons at Duke University Hospital Use Advanced Preservation and Transportation System to Safeguard Donor Heart During Journey Between Donor and Recipient